NCT03802786View on ClinicalTrials.gov

Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 6, 2018

Primary Completion Date

July 3, 2019

Study Completion Date

July 8, 2019

Conditions
Hepatic Impairment
Interventions
DRUG

Imeglimin

Single administration dose of imeglimin

Trial Locations (1)

Unknown

Apex, Munich

Sponsors

Lead Sponsor

Poxel SA
All Listed Sponsors
lead

Poxel SA

INDUSTRY

NCT03802786 - Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects | Biotech Hunter | Biotech Hunter